Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BR-790 by Jiangxi Qingfeng Pharmaceutical for Solid Tumor: Likelihood of Approval
BR-790 is under clinical development by Jiangxi Qingfeng Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData,...
BR-790 by Jiangxi Qingfeng Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
BR-790 is under clinical development by Jiangxi Qingfeng Pharmaceutical and currently in Phase I for Non-Small Cell Lung Cancer. According...
BR-790 by Jiangxi Qingfeng Pharmaceutical for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
BR-790 is under clinical development by Jiangxi Qingfeng Pharmaceutical and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC)....
BR-790 by Jiangxi Qingfeng Pharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
BR-790 is under clinical development by Jiangxi Qingfeng Pharmaceutical and currently in Phase I for Head And Neck Squamous Cell...